RB1 and cancer: After whole exome analysis is carried out on the patient with the shortest response, we observed the appearance of RB1 loss-of-function mutation that could be a mechanism of resistance to MEK inhibitors in <i>RAS</i>- of <i>RAF</i>-mutated cancers.